Pemetrexed prolongs survival in patients with malignant pleural mesothelioma or non-small-cell lung cancer

被引：0
|
作者：
不详
机构：
来源：
Drugs & Therapy Perspectives | 2005年 / 21卷 / 10期
关键词：
D O I：
10.2165/00042310-200521100-00001
中图分类号：
学科分类号：
摘要：
Pemetrexed is a multi-targeted antifolate that inhibits DNA and RNA synthesis. It is used, with cisplatin, in the treatment of malignant pleural mesothelioma (MPM) in patients who are not candidates for surgery and also as second-line monotherapy in locally advanced or metastatic non-small-cell lung cancer (NSCLC). Pemetrexed has favourable tolerability when supplemented with folic acid and cyanocobalamin (vitamin B12). It is clinically active against both MPM and NSCLC, with activity non-inferior to docetaxel in treating refractory or recurrent NSCLC and, with concomitant cisplatin, superior efficacy to single-agent cisplatin in treating unresectable MPM. © 2005 Adis Data Information BV. All rights reserved.
引用
收藏
页码：1 / 4
页数：3
相关论文
共 50 条
  • [41] Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
    Skrickova, Jana
    Bortlicek, Zbynek
    Hejduk, Karel
    Pesek, Milos
    Kolek, Vitezslav
    Tomiskova, Marcela
    Grygarkova, Ivona
    Koubkova, Leona
    Cernovska, Marketa
    Roubec, Jaromir
    Salajka, Frantisek
    Zemanova, Milada
    Coupkova, Helena
    Satankova, Monika
    Marel, Milosalav
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [42] Rechallenge with pemetrexed- based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer
    Zhuo, Ming-Lei
    Bai, Hua
    Wang, Zhi-Jie
    Duan, Ran-Chun
    An, Tong-Tong
    Wu, Mei-Na
    Zhao, Jun
    Wang, Yu-Yan
    Wang, Shu-Hang
    Wang, Jie
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (06) : 953 - 959
  • [43] Natural Course of Asymptomatic Malignant Pleural Effusion in Non-Small-Cell Lung Cancer Patients: A Multicenter Retrospective Study
    Roh, J.
    Kim, I.
    Son, J.
    Eom, J.
    Ahn, H.
    Lee, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [44] Retrospective study of pemetrexed's safety and effectivity in malignant pleural mesothelioma and non-microcytic lung cancer
    Picaza, E.
    Agustin, M. J.
    Varela, I
    Alonso, V
    Idoipe, A.
    Palomo, P.
    ATENCION FARMACEUTICA, 2008, 10 (02): : 73 - 78
  • [45] Natural course of asymptomatic malignant pleural effusion in non-small-cell lung cancer patients: a multicenter retrospective study
    Eom, Jung Seop
    Roh, Ji Yeon
    Kim, Insu
    Seol, Hee Yun
    Lee, Min Ki
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [46] Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions
    Perng, RP
    Chen, YM
    Wu, MF
    Chou, KC
    Lin, WC
    Liu, JM
    Whang-Peng, J
    RESPIRATORY MEDICINE, 1998, 92 (03) : 473 - 479
  • [47] Prognosis of non-small-cell lung cancer patients with positive pleural lavage cytology
    Nakao, Masayuki
    Hoshi, Rira
    Ishikawa, Yuichi
    Matsuura, Yosuke
    Uehara, Hirofumi
    Mun, Mingyon
    Nakagawa, Ken
    Okumura, Sakae
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2015, 20 (06) : 777 - 782
  • [48] Efficacy of Osimertinib in Patients with Non-Small-Cell Lung Cancer (NSCLC) and Pleural Effusion
    Manabe, Saki
    Sata, Masafumi
    Murakami, Shuji
    Kondo, Tetsuro
    Kato, Terufumi
    Saito, Haruhiro
    Sekine, Akimasa
    Ogura, Takashi
    Yamada, Kouzo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1269 - S1269
  • [49] Maintenance therapy for metastatic non-small-cell lung cancer - the role of pemetrexed
    Katz, Youval
    Somer, Robert A.
    LUNG CANCER-TARGETS AND THERAPY, 2010, 1 : 1 - 7
  • [50] Continued gefitinib treatment after disease stabilization prolongs survival of patients with advanced non-small-cell lung cancer.
    Hotta, K
    Matsuo, K
    Ueoka, H
    Kiura, K
    Tabata, M
    Harita, S
    Gemba, K
    Yonei, T
    Bessho, A
    Tanimoto, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 642S - 642S
12345